NOVARTIS AG-REG NVSEF

US Healthcare Pharmaceutical Preparations
$158.24
+3.2%
52w: $111.38 – $171.29

Latest 13F among current holders filed 1 month ago (May 12, 2026)

Price — last 12 months

research preview data
111.38141.33171.29
Jun 20, 2025 Jul 2, 2026
Institutional holders
2
+0 QoQ
13F value
$6.8M
+0.4% QoQ
Smart-money holders
0
signal tier ≥ 2
New smart buyers
0
Q1 2026

Institutional value by quarter

$18.8M
Q1 2024
$33.2M
Q2 2024
$26.3M
Q3 2024
$20.1M
Q4 2024
$36.0M
Q1 2025
$31.1M
Q2 2025
$23.9M
Q3 2025
$6.8M
Q4 2025
$6.8M
Q1 2026

Number of holders

3
Q1 2024
3
Q2 2024
2
Q3 2024
2
Q4 2024
4
Q1 2025
4
Q2 2025
4
Q3 2025
2
Q4 2025
2
Q1 2026

Who owns NVSEF?

Q1 2026 filings
FundTypeSharesValue% of fundChange
PARTNERS CAPITAL INVESTMENT GROUP, LLP Wealth advisor28.2K$4.3M0.2%-9.9%
Generali Investments CEE, investicni spolecnost, a.s. Other17.1K$2.6M0.1%-5.5%

Exits are not a bearish signal: our backtest shows stocks specialists exit keep outperforming for 3+ quarters — selling usually means profit-taking, not a forecast.